Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

计划入组 43 人 · 首次发布于 2023 年 1 月 18 日

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

计划入组 30 人 · 首次发布于 2024 年 10 月 30 日

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

计划入组 42 人 · 首次发布于 2023 年 10 月 11 日

Novobiocin

C₃₁H₃₆N₂O₁₁ · Rx

protein kinase C epsilon/theta inhibitors (Devgen)

T7 RNA polymerase (Bioaugen)

Acurx Pharmaceuticals

United States

Thea

United States

LABORATOIRES THEA

France

Artios Reports First Clinical Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO 2025

Artios Pharma Raises $115M Series D to Advance Next-Generation DNA Damage Repair Cancer Therapies

MOMA Therapeutics Initiates Phase 1 Trial for Novel DNA Repair Inhibitor MOMA-313